Subsequent Event (Details) - Subsequent Event [Member] - Asset Purchase Agreement [Member] $ in Thousands	Apr. 30, 2017 USD ($)
1st Order Pharmaceuticals, Inc. [Member]
Subsequent Event [Line Items]
Near term upfront and milestone consideration	$ 1,100
1st Order Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. [Member] | Clinical Development Milestones [Member]
Subsequent Event [Line Items]
Future potential payments	1,000
1st Order Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. [Member] | Regulatory Milestone [Member]
Subsequent Event [Line Items]
Future potential payments	13,000
1st Order Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. [Member] | Sales-based and Other Milestones [Member]
Subsequent Event [Line Items]
Future potential payments	33,600
1st Order Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. [Member] | Pre-commercial and Single Digit Percentage Royalty on Commercial Sales Milestone [Member]
Subsequent Event [Line Items]
Future potential payments	$ 1,500